Sarepta Therapeutics Cash Flow - Quarterly (NASDAQ:SRPT)

Add to My Stocks
$31.41 $1.25 (3.83%) SRPT stock closing price Jan 23, 2017 (Closing)

The Sarepta Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Sarepta Therapeutics profits one has to check the income statement and for Sarepta Therapeutics debt one has to check the balance sheet. Sarepta Therapeutics cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents.  Sarepta Therapeutics had cash and cash equivalents of $73.55M at the beginning of the quarter and $395.14M at quarter end for 2016-Q3.   Sarepta Therapeutics has a positive cash and cash equivalents change of $314.83M. View details of Sarepta Therapeutics cash flows for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q3 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1
Sarepta Therapeutics Net Income Cash Flow
-178.81M-59.77M-220.03M-155.34M-103.41M-61.55M-135.78M-91.37M-62.14M-28.27M
Depreciation Depletion Amortization Cash-Flow4.42M1.63M5.89M4.68M3.18M1.59M6.12M4.34M2.61M1.04M
Net Increase (Decrease) in Assets Liabilities-13.83M-9.4M31.98M6.51M8.12M2.32M-22.13M-33.5M-25.24M-8.63M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net23.64M6.85M32.68M25.94M20.21M14.28M23.26M17.44M17.01M7.59M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
-164.58M-60.68M-149.46M-118.19M-71.87M-43.34M-128.53M-103.09M-67.76M-28.26M
Increase (Decrease) in Prop Plant And Equipment-2.42M-1.16M-3.4M-2.31M-1.16M-0.53M-25.44M-22.3M-9.84M-5.32M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments112.1M21M13.24M81.52M49.01M44.75M-132.2M-182.34M-174.69M-176.66M
Other Cash Inflow (Outflow) from Investment Activities-1.09M-0.41M-1.43M-0.98M-0.64M-0.39M-1.38M-1.06M-0.62M-0.29M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
108.58M19.42M8.41M78.22M47.21M43.82M-159.03M-205.7M-185.16M-182.28M
Issuance (Purchase) of Equity Shares375.91M1.48M130.8M5.2M0.97M0.43M104.24M104.2M98.77M2.71M
Issuance (Repayment) of Debt Securities-5.07M-2.52M17M17.02M19.68M-0.02M-0.09M-0.07M-0.04M-0.02M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Sarepta Therapeutics Net Cash from (used by) Financing Activities
370.84M-1.03M147.8M22.23M20.65M0.4M104.15M104.13M98.72M2.69M
Effect of Exchange Rate Changes on Cash----------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
314.83M-42.3M6.75M-17.73M-4.01M0.88M-183.41M-204.66M-154.21M-207.86M
Cash & Equivalents at Beginning of Year73.55M187.66M39.9M33.58M48.27M11.19M24.8M20.15M34.59M16.65M
Cash & Equivalents at Year End395.14M38M80.3M55.81M69.53M74.43M73.55M52.29M102.75M49.1M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

1:11
SRPT
While Sarepta Therapeutics stock price history provides the price history of a stock, Sarepta Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:
  • Sarepta Therapeutics has cash of $395.14M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Sarepta Therapeutics stock price.
  • Cash Flow from operating activities: Operating activities include the core business activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $370.84M for Sarepta Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.
.